Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
about
Spotlight on ixazomib: potential in the treatment of multiple myelomaA single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myelomaPractical Approaches to the Management of Dual Refractory Multiple Myeloma.Is immunotherapy here to stay in multiple myeloma?
P2860
Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunotherapy for Multiple Mye ...... cines, and Cellular Therapies.
@en
type
label
Immunotherapy for Multiple Mye ...... cines, and Cellular Therapies.
@en
prefLabel
Immunotherapy for Multiple Mye ...... cines, and Cellular Therapies.
@en
P2093
P2860
P1476
Immunotherapy for Multiple Mye ...... cines, and Cellular Therapies.
@en
P2093
David Avigan
Hearn Jay Cho
Rebecca Karp Leaf
P2860
P2888
P304
P356
10.1007/S11899-015-0283-0
P577
2015-09-04T00:00:00Z
P6179
1022279516